Shawn Rose
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
Shawn Rose currently works at Nkarta, Inc., as Chief Medical Officer, Head-Research & Development from 2025.
Dr. Rose also formerly worked at Vividion Therapeutics, Inc., as Chief Development Officer-Immunology and Magenta Therapeutics, Inc., as Senior Vice President & Head-Clinical Development.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NKARTA, INC. -.--% | 17/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NKARTA, INC. | Director Técnico/Científico/I+D | 23/06/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| MAGENTA THERAPEUTICS | Director Técnico/Científico/I+D | 07/02/2023 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines | Health Technology |
Nkarta, Inc.
Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.